SCHEMBL31460150

SCHEMBL31460150

CCOC(=O)c1c(N)sc2c(O[Si](C(C)C)(C(C)C)C(C)C)c(Cl)ccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.57
▸ MEN1 O00255 4/20 0.57
▸ KMT2A Q03164 4/20 0.57
▸ ALOX15 P16050 3/20 0.57
▸ USP2 O75604 1/20 0.57
▸ NPSR1 Q6W5P4 2/20 0.56
▸ GAA P10253 4/20 0.56
▸ TSHR P16473 2/20 0.56
▸ MAPK1 P28482 3/20 0.47
▸ GRM6 O15303 5/20 0.44
▸ ALDH1A1 P00352 8/20 0.44
▸ HPGD P15428 5/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ FHIT P49789 1/20 0.41
▸ MPI P34949 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ PRKCZ Q05513 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31460158 0.85 MAPT (0.60) MAPTMEN1KMT2AALOX15USP2
SCHEMBL31459922 0.81 MAPT (0.73) MAPTMEN1KMT2AALOX15USP2
SCHEMBL31460309 0.72 MAPT (1.00) MAPTMEN1KMT2AALOX15USP2
SCHEMBL2925906 0.71 TSHR (0.67) MAPTMEN1KMT2AALOX15USP2
SCHEMBL6642029 0.71 CA12 (0.41) MAPTMEN1KMT2ANPSR1GAA
SCHEMBL30959660 0.69 MAPT (0.51) MAPTMEN1KMT2AALOX15USP2
SCHEMBL3984848 0.68 MAPT (0.67) MAPTMEN1KMT2AALOX15USP2
SCHEMBL3990578 0.67 MAPT (0.64) MAPTMEN1KMT2AALOX15USP2
SCHEMBL16521093 0.67 MAPT (0.78) MAPTMEN1KMT2AALOX15USP2
SCHEMBL15184999 0.67 MAPT (0.78) MAPTMEN1KMT2AALOX15USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154163-A1 Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors ENANTA PHARMACEUTICALS, INC. 2025-05-15 — — US disclosed
WO-2025090868-A1 PYRIMIDINONE-CONTAINING 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2025-05-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154163-A1 Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors HSD17B13, HSD17B1, HSD11B1 MAPT 3628/4885MEN1 1840/4885KMT2A 3204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback